Saturday, June 1, 2024, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Prostate Cancer

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director for Clinical Research
Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute
University of Utah (NCI-CCC)
Salt Lake City, Utah

Emmanuel S Antonarakis, MD
Clark Endowed Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Tanya B Dorff, MD
Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
and Therapeutics Research
Section Chief, Genitourinary Cancer Program
City of Hope National Medical Center
Los Angeles, California


Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair
in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology
and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Discussion Topics

  • Optimizing the Management of Nonmetastatic Prostate Cancer
  • Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer
  • New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Role of Novel Radiopharmaceuticals for mCRPC
  • Promising Investigational Approaches for Patients with Prostate Cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biological factors.
  • Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Agarwal has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committees: Aadi Bioscience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curium, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus; Consulting Agreements: EcoR1 Capital LLC, Hookipa Pharma Inc, Lilly, Menarini Silicon Biosystems, Z-Alpha; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, MacroGenics Inc, Merck, Novartis, Orion Corporation, Seagen Inc; Patent Holder: QIAGEN. Dr Dorff — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Sanofi; Consulting Agreement: Bayer HealthCare Pharmaceuticals. Dr Smith — Advisory Committees: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Consulting Agreements: Ambrx, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Stock Options/Ownership — Public Company: Ambrx.

MODERATOR — Dr Armstrong — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, GoodRx, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Epic Sciences, Exact Sciences Corporation, Exelixis Inc, Forma Therapeutics, GoodRx, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Dendreon Pharmaceuticals Inc, Forma Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: National Cancer Institute, National Institutes of Health, Prostate Cancer Foundation/Movember, US Department of Defense.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical and radiation oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration
Thank you for your interest in our CME program taking place in Chicago. At this time online registration to attend this event in person is closed. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME, FIRST SERVED BASIS. Our onsite registration desk will be open at 6:30 PM central time on Saturday, June 1st. If you are interested in attending, please visit our registration desk outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on the shuttle service is available on the 2024 ASCO Annual Meeting website.

Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.